Pharmaceutical Industry Reports Testosterone Replacement Therapy | Page 2

REPORT DESCRIPTION
Testosterone Replacement Therapy Market – Overview
Testosterone Replacement Therapy (TRT) or low testosterone therapy is commonly called hormone therapy for
men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men
is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone.
Hypogonadism may be primary, due to a problem with the testes or secondary due to a problem with the
hypothalamus or pituitary gland or combined: primary and secondary. Primary hypogonadism is caused due to
genetic abnormalities, testicular trauma, orchitis, radiation treatment or chemotherapy, while secondary
hypogonadism is caused due to genetic abnormalities of pituitary and hypothalamus.
Furthermore, functional causes of hypogonadism are mainly attributed to the severe psychological or emotional
stress, obesity (WHO grade III or IV- BMI > 30), nutritional deficiency or eating disorders, untreated obstructive
sleep apnea, medication such as opioids, androgens, glucocorticoids, anabolic steroids; chronic systemic illness
caused due to kidney, lung, heart failure, diabetes mellitus, HIV infection, Crohn’s disease, and aging.
Testosterone replacement therapy is promising technology for improving symptoms of hypogonadism and to raise
the low testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include,
increase in muscle tissue, overall surge in body energy, and significant decrease in depression symptoms.
© Coherent market Insights. All Rights Reserved